Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation—A Blood or Marrow Transplant Survivor Study Report

Transplantation and Cellular Therapy(2021)10.1016/j.jtct.2021.06.014Source: DataRank Database

Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantation—A Blood or Marrow Transplant Survivor Study Report is a research paper published in Transplantation and Cellular Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.26)OA: greenTopics (31)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Yanjun Chen ORCID,Jessica Wu ORCID,Lindsey Hageman ORCID,Joshua Richman ORCID,Liton Francisco ORCID

Live enrichment

PubMed:34153501 PMC:PMC8478837 OpenAlex:https://openalex.org/W3174462334

National Institutes of Health

Grant: U01 CA213140

NCI NIH HHS

Grant: R01 CA078938

NCI NIH HHS

Grant: P01 CA030206

National Institutes of Health

Grant: 5U01CA213140-02

BMT Survivor Study-2 (BMTSS-2)

Janssen Pharmaceuticals

Amgen

Celgene

FWCI

0.26

Citation Percentile

0.5%

Citation Trend

2022

2025

greenLicense: CC BY NC ND

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8478837

publisherhttps://api.elsevier.com/content/article/PII:S2666636721009982?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636721009982?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtct.2021.06.014

Fields of Study

Multiple Myeloma Research and TreatmentsPeptidase Inhibition and AnalysisCancer Treatment and Pharmacology03 medical and health sciences0302 clinical medicine

MeSH Terms

Bone MarrowHumansMultiple MyelomaProspective StudiesTransplantation, AutologousSurvivorsPeripheral Blood Stem Cell Transplantation

Keywords

MedicineMultiple myelomaHazard ratioCumulative incidenceInternal medicineProportional hazards modelTransplantationConfidence intervalCohortThalidomideSurgeryAutologous Peripheral Blood Stem Cell TransplantationLate MortalityPeripheral Blood Stem Cell TransplantationBone MarrowHumansProspective StudiesSurvivorsTransplantation, Autologous

Sustainable Development Goals

SDG 0: Good health and well-being